BCLI

1.68

6.67% -0.12

Dopo l'orario di chiusura: 1.59 -0.09 -5.36%

Brainstorm Cell Therapeutics Inc (BCLI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BCLI Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.80

Aprire:

$1.81

Volume 24 ore:

109.56K

Relative Volume:

2.16

Capitalizzazione di mercato:

$8.93M

Reddito:

Utile/perdita netta:

$-16.63M

Rapporto P/E:

-2.8475

EPS:

-0.59

Flusso di cassa netto:

$-21.84M

1 W Prestazione:

-15.15%

1M Prestazione:

-27.90%

6M Prestazione:

-70.53%

1 anno Prestazione:

-34.50%

Intervallo 1D:

$1.585

$1.86

Intervallo di 1 settimana:

$1.585

$2.00

Portata 52W:

$1.585

$11.89

Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile

Nome

Brainstorm Cell Therapeutics Inc

Settore

Healthcare (1182)

Industria

Biotechnology (671)

Telefono

201-488-0460

Indirizzo

1325 AVENUE OF AMERICAS, NEW YORK, NY

Dipendente

Cinguettio

@BrainStormCell

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

BCLI's Discussions on Twitter

Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-02-04	Aggiornamento	Maxim Group	Hold → Buy
2020-11-17	Downgrade	Maxim Group	Buy → Hold
2016-12-19	Reiterato	Maxim Group	Buy
2015-12-22	Reiterato	Maxim Group	Buy

Brainstorm Cell Therapeutics Inc Borsa (BCLI) Ultime notizie

Oct 30, 2024

BrainStorm regains Nasdaq compliance with bid price rule By Investing.com - Investing.com South Africa

Oct 30, 2024

BrainStorm regains Nasdaq compliance with bid price rule - Investing.com India

Oct 30, 2024

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - StockTitan

Oct 30, 2024

Oct 29, 2024

Neuromuscular Disease Therapeutics Market Statistical - openPR

Oct 29, 2024

Oct 28, 2024

BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - Nasdaq

Oct 28, 2024

Oct 27, 2024

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update - MarketBeat

Oct 27, 2024

Oct 18, 2024

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat

Oct 18, 2024

Oct 17, 2024

Amyotrophic Lateral Sclerosis (ALS) Market: Detailed Analysis - openPR

Oct 17, 2024

Oct 16, 2024

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmBCLI - AsiaOne

Oct 16, 2024

Oct 11, 2024

Stem Cell Therapy Market Projected to Reach $831.9 Million By 2032 - 대구포스트

Oct 11, 2024

Oct 10, 2024

Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 91.1% - MarketBeat

Oct 10, 2024

Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Report By Type, Application and Geography - Elektrotransports.lv

Oct 10, 2024

Oct 09, 2024

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - MarketBeat

Oct 09, 2024

Oct 07, 2024

BCLIBrainstorm Cell Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Oct 07, 2024

BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - StockTitan

Oct 07, 2024

Oct 04, 2024

Gene and Cell Therapies for CNS Disorders Market to Experience - openPR

Oct 04, 2024

Oct 02, 2024

Brainstorm cell therapeutics CEO acquires $11,308 in stock By Investing.com - Investing.com Canada

Oct 02, 2024

Brainstorm cell therapeutics CEO acquires $11,308 in stock - Investing.com

Oct 02, 2024

Oct 01, 2024

Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials - TipRanks

Oct 01, 2024